



#14
7648

59597-D/JPW/AJM/DRM

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Neil T. Parkin and Rainer A. Ziermann
Serial No. : 09/766,344
Filed : January 19, 2001
For : MEANS AND METHODS FOR MONITORING PROTEASE
INHIBITOR ANTIRETROVIRAL THERAPY AND GUIDING
THERAPEUTIC DECISIONS IN THE TREATMENT OF
HIV/AIDS

1185 Avenue of the Americas
New York, New York 10036
October 9, 2002

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

OCT 18 2002

Sir:

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following disclosures, which are listed on Form PTO-1449 (**Exhibit A**). A copy of the disclosures listed below as items 1-3 are attached as **Exhibits 1-3**.

1. U.S. Patent No. 5,837,464 (Capon et al.) issued November 17, 1998;
2. Young, B. et al., Resistance Mutations In Protease And Reverse Transcriptase Genes Of Human Immunodeficiency Virus Type 1 Isolates From Patients With Combination Antiretroviral Therapy Failure, Journal of Infectious Diseases, Vol. 178, No.5, pages 1497-1501 (November 1998); and
3. Hertogs et al., A Rapid Method For Simultaneous Detection Of Phenotypic Resistance To Inhibitors Of Protease And

Applicants : Neil T. Parkin and Rainer A. Ziermann
Serial No. : 09/766,344
Filed : January 19, 2001
Page 2

Reverse Transcriptase In Recombinant Human Immunodeficiency
Virus Type 1 Isolates from Patients Treated With
Antiretroviral Drugs, Antimicrobial Agents And
Chemotherapy, Vol. 42, No. 2, pages 269-276 (February
1998).

PCT International Application No. PCT/US02/01682, filed January
8, 2002 is a foreign counterpart application of the subject
application. A Search Report was issued on July 9, 2002 in
connection with PCT/US02/01682. A copy of the Search Report is
attached hereto as **Exhibit B**. The above listed references 1-3
were cited in the Search Report.

If a telephone interview would be of assistance in advancing
prosecution of the subject application, applicants' undersigned
attorneys invite the Examiner to telephone them at the number
provided below.


^

^

Applicants: Neil T. Parkin and Rainer A. Ziermann
Serial No.: 09/766,344
Filed : January 19, 2001
Page 3


No fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Alan J. Morrison
Registration No. 37,399
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents Washington, D.C. 20231.


Alan J. Morrison
Reg. No. 37,399

10/09/02
Date

Form PBQ-1449

**U.S. Department of
Commerce
Patent and Trademark Office**

Atty. Docket No.
2793/59597-D/JPW/AJM/DRM

Serial No.
09/766,344

Applicants
Neil T. Parkin and Rainer A. Ziermann

Filing Date
January 19, 2001

Group
1648

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	<p>Young, B. et al., Resistance Mutations In Protease And Reverse Transcriptase Genes Of Human Immunodeficiency Virus Type 1 Isolates From Patients With Combination Antiretroviral Therapy Failure, <u>Journal Of Infectious Diseases</u>, Vol. 178, No. 5, pages 1497-1501 (November 1998).</p>
	<p>Hertogs et al., A Rapid Method For Simultaneous Detection Of Phenotypic Resistance To Inhibitors Of Protease And Reverse Transcriptase In Recombinant Human Immunodeficiency Drugs, <u>Antimicrobial Agents And Chemotherapy</u>, Vol. 42, No. 2, pages 269-276 (February 1998).</p>

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.